Clinical trials: CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.
- Trial name
- NCT01625182
- Testing
- Fingolimod
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP.
Chronic Inflammatory Demyelinating Polyneuropathies (CIDP) are acquired, autoimmune and inflammatory neuropathies leading mainly to gait disorders in patients.
- Trial name
- ESCAL-PIDC (NCT05492604)
- Testing
- Clinical examination, Functional scales, Walking test
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Bordeaux
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to…
- Trial name
- NCT05327114
- Testing
- Nipocalimab
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Trial name
- ADHERE (NCT04281472)
- Testing
- efgartigimod PH20 SC in stage B
- Where
- 216 sites in United States, Austria and 23 more
- Volunteers
- 322 people
- Sponsor
- argenx
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Vasculitic Neuropathy
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
The project aims to investigate the validity, and reliability of outcome measures of muscle strength, functioning (gait, balance, and fine motor skills), physical activity, and patient-reported outcome measures of functioning…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Vasculitic Neuropathy, POEMS Syndrome, Multifocal Motor Neuropathy
- Trial name
- PolyImPAct (NCT06040567)
- Testing
- Validity and reliability of outcome measures in polyneuropathy, Healthy controls
- Where
- Denmark
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- NCT00962429
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Oregon Health and Science University
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and…
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Trial name
- NCT07264426
- Testing
- Efgartigimod PH20 SC
- Where
- 23 sites in United States, Germany
- Volunteers
- 200 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyneuropathy
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline.
- Trial name
- NCT01824251
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
This is safety study. Subjects will be undergoing the surgical procedure of nerve biopsy. After routine surgery without grafting, patients develop swelling, redness, tenderness and dysesthesia at the biopsy site.
- Conditions
- Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Vasculitic Neuropathy (Disorder), Amyloidosis
- Trial name
- NCT03584022
- Testing
- Biopsy + Nerve Repair, Biopsy Only
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Neurological Autoimmune Diseases
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases.
- Trial name
- NCT04687332
- Testing
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- University Medical Center Mainz
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
Primary objective: To assess the efficacy of I10E administered at a reduced maintenance dose in sustaining CIDP response after an initial 6-month treatment in PRISM study. (I10E-1302).
- Trial name
- PRISM2 (NCT02317562)
- Testing
- I10E
- Where
- 30 sites in France, Italy and 4 more
- Volunteers
- 19 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Obesity, Immune Deficiency
Immunoglobulin G Therapy Dose Optimization
The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients.
- Trial name
- NCT04818177
- Testing
- Institutional standard intravenous immune globulin treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rutgers, The State University of New Jersey
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care.
- Trial name
- MOBILIZE (NCT06290128)
- Testing
- Riliprubart
- Where
- 132 sites in United States, Argentina and 22 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
Chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired…
- Trial name
- NCT02271724
- Testing
- Lumbar puncture, Blood sample
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- University of Aarhus
CIDP
Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP patients. 25 patients with a diagnosis of CIDP according to European criteria, naïve of treatment, will be included and followed for 1…
- Trial name
- BIOMARK (NCT02629796)
- Testing
- CIDP treated (IVIG)
- Where
- 18 sites in France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
CIDP and MMN are part of a group of chronic inflammatory conditions that affect the peripheral nervous system. In CIDP, there is chronic inflammation of the peripheral nerves and nerve roots leading to demyelination.
- Trial name
- digG (NCT04356781)
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Walton Centre NHS Foundation Trust
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin.
- Trial name
- CASCA (NCT06798012)
- Testing
- TAK-411
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Chronic Inflammatory Demyelinating Polyneuropathy
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropathy, CIDP.
- Trial name
- NCT04825626
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation